News

Rideshare giants Uber and Lyft partner with providers to help get patients to their medical appointments, as well as improve the overall patient experience. Here’s five takeaways from industry watchers.

The Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.

HHS Secretary Alex M. Azar II lays out top four HHS initiatives and calls on payers and providers to align.

Sadly, President Trump has issued an executive order to expand these plans under the guise of consumer choice and lower costs.

This first article in our new leadership series explores how managed care executives can cultivate smart ideas and stay ahead of the competition.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage.

During the worst flu season in years, FDA is warning consumers about fraudulent and counterfeit flu and antiviral products from online pharmacies.

In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.

The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.

Reducing hospital readmissions requires just the right mix of clinical expertise and predictive analytics. Here are two health systems that are hitting their stride.

Your net promoter score could be influencing your business. Here’s what it is and how to improve it.

A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.

FDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, agreed to destroy the supplements, and is again warning the public about kratom.

Eye-opening research by NTT DATA Services sheds light on healthcare consumer satisfaction with virtual versus human agents.

Is your organization on pace with the biggest healthcare technology trends? Here’s your chance to find out.

Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.

A study from Human Rights Watch has eye-opening findings about antipsychotic drug prescribing in U.S. nursing homes.

Managed care organizations are looking for new skills in healthcare leaders (and in some cases hiring for completely new leadership roles). Here are four emerging trends to watch.

We asked the Managed Healthcare Executive board to share their favorite app-for work or for play. Here’s what they said.

Anthem’s decision has sparked criticism and concern, but could it reduce healthcare spending? Experts weigh in.

Retail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.

A new survey from Sage Growth Partners offers new ideas on executives’ application and adoption of telemedicine technology.

FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.

FDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage